Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology | Zendy

Marialuisa Moccia | Zendy; Brendan Frett | Zendy; Lingtian Zhang | Zendy; Naga Rajiv Lakkaniga | Zendy; David C. Briggs | Zendy; Rakhee Chauhan | Zendy; Annalisa Brescia | Zendy; Giorgia Federico | Zendy; Wei Yan | Zendy; Massimo Santoro | Zendy; Neil Q. McDonald | Zendy; Hongyu Li | Zendy; Francesca Carlomagno | Zendy

Open Access

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

Author(s) -

Marialuisa Moccia,

Brendan Frett,

Lingtian Zhang,

Naga Rajiv Lakkaniga,

David C. Briggs,

Rakhee Chauhan,

Annalisa Brescia,

Giorgia Federico,

Wei Yan,

Massimo Santoro,

Neil Q. McDonald,

Hongyu Li,

Francesca Carlomagno

Publication year - 2020

Publication title -

journal of medicinal chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.01

H-Index - 261

eISSN - 1520-4804

pISSN - 0022-2623

DOI - 10.1021/acs.jmedchem.9b01336

Subject(s) - chemistry , pharmacology , cancer research , vandetanib , drug discovery , in vivo , kinase insert domain receptor , tyrosine kinase , receptor , vegf receptors , biochemistry , biology , vascular endothelial growth factor , vascular endothelial growth factor a , microbiology and biotechnology

RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo metabolite of Pz-1 is its less active demethylated pyrazole analogue. Using bioisosteric substitution methods, here, we report the identification of NPA101.3, lacking the structural liability for demethylation. NPA101.3 showed a selective inhibitory profile and an inhibitory concentration 50 (IC 50 ) of <0.003 μM for both RET and VEGFR2. NPA101.3 inhibited phosphorylation of all tested RET oncoproteins as well as VEGFR2 and proliferation of cells transformed by RET. Oral administration of NPA101.3 (10 mg/kg/day) completely prevented formation of tumors induced by RET/C634Y-transformed cells, while it weakened, but did not abrogate, formation of tumors induced by a control oncogene (HRAS/G12V). The balanced synchronous inhibition of both RET and VEGFR2, as well the resistance to demethylation, renders NPA101.3 a potential clinical candidate for RET-driven cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research